A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Solid Tumor|Recurrent Solid Tumor|Advanced Solid Tumor|Urinary Bladder Neoplasm|Triple Negative Breast Cancer|Non-small Cell Lung Cancer|Esophageal Cancer|Pancreatic Cancer|Ovarian Cancer|Cervical Cancer|Head and Neck Squamous Cell Carcinoma|Prostate Cancer|Renal Pelvis Cancer|Bladder Cancer
Interventions: DRUG: LY4101174
Sponsor: Eli Lilly and Company
Collaborators: Loxo Oncology, Inc.